Clinical Trial

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Study acronym: ARGiNAUT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-26
Trial Details
NCT Number NCT07652658
Lead Sponsor AstraZeneca
Conditions Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 359 participants
Start Date 2026-06-11
Primary Completion 2028-09-14 (estimated)
Study Completion 2028-09-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-25